AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00560417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered subcutaneously once a day at bedtime
Study NCT00622726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
Study NCT01274442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample will be taken to identify relevant genetic polymorphisms.
Study NCT01274442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample will be taken to identify relevant genetic polymorphisms.
Study NCT01935687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using of instrumented wheel
Description: Using of instrumented wheel
Study NCT01935687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using of ergometer roller
Description: Using of ergometer roller
Study NCT02307721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Description: Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
Study NCT02307721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular naloxone
Description: Administer 2 mL, dose intramuscular naloxone 0,8 mg
Study NCT02307721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
Study NCT02307721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
Study NCT02307721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Unidose
Description: This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
Study NCT02772965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.
Study NCT02772965 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill (placebo)
Description: 1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.
Study NCT02410902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-AT
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Study NCT02410902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Study NCT01477151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volatile anesthetic
Description: The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration.
Study NCT00622726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laser for ROP
Description: Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
Study NCT01477151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volatile anesthetic
Description: The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration.
Study NCT03087825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation without inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
Study NCT03087825 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: preoxygenation without inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
Study NCT03087825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation with inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
Study NCT03087825 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: preoxygenation with inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
Study NCT01714050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Study NCT01714050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy (LT)
Description: SunRay (SunBox Company, Gaithersburg, MD)
Study NCT04341259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
Study NCT03483311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy before and after NB-UVB phototherapy
Description: skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
Study NCT03404401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: Oral bowel preparation
Study NCT03404401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol bowel preparation
Description: Oral bowel preparation
Study NCT00890552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle.
Study NCT00890552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle
Study NCT00746330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg pMDI (F12M)
Description: Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
Study NCT00746330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg DPI (F12D)
Description: Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
Study NCT00746330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12D
Description: Placebo to formoterol fumarate DPI delivered via DPI
Study NCT00890552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle
Study NCT00746330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12M/MFF
Description: Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
Study NCT03914118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative modafinil + postoperative placebo
Description: 200 mg modafinil pre-operatively and placebo immediately post-operatively.
Study NCT03914118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative modafinil + postoperative modafinil
Description: 200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
Study NCT03914118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative placebo + postoperative placebo
Description: Placebo pre-operatively and placebo immediately post-operatively.
Study NCT02843659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: Specified dose on specified days
Study NCT02843659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Description: Specified dose on specified days
Study NCT02843659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT02843659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04339569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical analysis
Description: 3D analysis of landing manoeuvres.
Study NCT04339569 — intervention group
Intervention type: OTHER
Intervention: Fatigue protocol
Description: A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
Study NCT02194101 — intervention group
Intervention type: PROCEDURE
Intervention: Supernormal oxygen delivery goal therapy
Description: A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
Study NCT03802838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
Study NCT03802838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
Study NCT03802838 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amisulpride
Description: Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
Study NCT03709719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab Injection
Description: Blinatumomab 28 μg/day : D1 to D28
Study NCT02669550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope
Description: In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
Study NCT02669550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposcope endoscope
Description: In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
Study NCT02324842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
Study NCT02324842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Study NCT01378195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based program for dementia caregivers
Description: Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
Study NCT00588328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: PET/CT scans
Study NCT01378195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational/Resources program
Description: Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
Study NCT00027820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00027820 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00027820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo nonmyeloablative PBSCT
Study NCT00027820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative PBSCT
Study NCT04149028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml
Description: intraovarian injection of 2 mml of PRP by laparoscopic guide
Study NCT04065568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKO-tool
Description: The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
Study NCT01946984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: endoscopy, retrograde cholangio-pancreaticography.
Study NCT01946984 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERCP
Description: endoscopy, retrograde cholangio-pancreaticography.
Study NCT01946984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac hydroxyethylpyrrolidine
Study NCT01946984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01185028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide With Pegylated Interferon And Ribavirin
Description: Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
Study NCT02188082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IvabRadine hemisulfate Sustained-release Tablets
Study NCT02188082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04086641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover foot
Description: A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
Study NCT04086641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy Storing Foot
Description: A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
Study NCT00027820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00027820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT02155374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sliding scale insulin
Study NCT02155374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate acting insulin
Study NCT01047995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir plus Darunavir/ritonavir
Description: Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.
Study NCT01047995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir plus Darunavir/ritonavir
Description: Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.
Study NCT02709993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
Study NCT00988741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
Study NCT00988741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is provided in a capsule form.
Study NCT02279524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study.